fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease

被引:0
|
作者
Paulsen, JS [1 ]
Zimbelman, JL
Hinton, SC
Langbehn, DR
Leveroni, CL
Benjamin, ML
Reynolds, NC
Rao, SM
机构
[1] Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA
[2] Carroll Coll, Dept Hlth Sci, Waukesha, WI USA
[3] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA
[4] Massachusetts Gen Hosp, Psychol Assessment Ctr, Boston, MA USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Functional MR imaging (fMRI) has been used to probe basal ganglia function in people with presymptomatic Huntington's disease (pre-HD). A previous fMRI study in healthy individuals demonstrated activation of the basal ganglia during a time-discrimination task. The current study was designed to examine the relative sensitivity of fMRI compared with that of behavioral testing and morphometric measurements in detecting early neurodegenerative changes related to Huntington's disease (HD). METHODS: Pre-HD participants were assigned to two groups based on estimated years to diagnosis of manifest disease: close < 12 years and far greater than or equal to 12 years. Age at disease onset was estimated using a regression equation based on the number of trinucleotide CAG repeats. The time-discrimination task required participants to determine whether a specified interval was shorter or longer than a standard interval of 1200 milliseconds. RESULTS: Participants in the close group performed more poorly on the time-task discrimination than did control subjects; however, no differences were observed between far participants and control subjects. Similarly, close participants had reduced bilateral caudate volume relative to that of control subjects, whereas far participants did not. On functional imaging, close participants had significantly less activation in subcortical regions (caudate, thalamus) than control subjects; far participants had an intermediate degree of activation. In contrast, far participants had hyperactivation in medial hemispheric structures (anterior cingulate, pre-supplementary motor area) relative to close and control subjects. CONCLUSION: Hyperactivation of medial prefrontal regions compensated for reduced subcortical participation during time discrimination in pre-HD. This pattern of brain activation may represent an early neurobiologic marker of neuronal dysfunction.
引用
收藏
页码:1715 / 1721
页数:7
相关论文
共 50 条
  • [41] Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease
    Reynolds, NC
    Prost, RW
    Mark, LP
    BRAIN RESEARCH, 2005, 1031 (01) : 82 - 89
  • [42] Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease
    Michelle E.Fullard
    James F.Morley
    John E.Duda
    Neuroscience Bulletin, 2017, 33 (05) : 515 - 525
  • [43] Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease
    Fullard, Michelle E.
    Morley, James F.
    Duda, John E.
    NEUROSCIENCE BULLETIN, 2017, 33 (05) : 515 - 525
  • [44] Olfactory Dysfunction as an Early Biomarker in Parkinson’s Disease
    Michelle E. Fullard
    James F. Morley
    John E. Duda
    Neuroscience Bulletin, 2017, 33 : 515 - 525
  • [45] Are gait and step initiation parameters early markers of Huntington's disease in presymptomatic mutation carriers?
    Dehal, A.
    Bleuse, S.
    Simonin, C.
    Delliaux, M.
    Roland, B.
    Defebvre, L.
    Dujardin, K.
    Krystkowiak, P.
    MOVEMENT DISORDERS, 2010, 25 (07) : S271 - S271
  • [46] A Computational Cognitive Biomarker for Early-Stage Huntington's Disease
    Wiecki, Thomas V.
    Antoniades, Chrystalina A.
    Stevenson, Alexander
    Kennard, Christopher
    Borowsky, Beth
    Owen, Gail
    Leavitt, Blair
    Roos, Raymund
    Durr, Alexandra
    Tabrizi, Sarah J.
    Frank, Michael J.
    PLOS ONE, 2016, 11 (02):
  • [47] Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium
    Harper, PS
    Lim, C
    Craufurd, D
    JOURNAL OF MEDICAL GENETICS, 2000, 37 (08) : 567 - 571
  • [48] Olfactory Dysfunction in Presymptomatic Alzheimer's Disease
    Wilson, Robert S.
    Arnold, Steven E.
    Schneider, Julie A.
    Bennett, David A.
    CHEMICAL SENSES, 2008, 33 (08) : S15 - S16
  • [49] Selection for presymptomatic testing for Huntington's disease: Who decides?
    Mansie, S
    Sheffield, L
    Forrest, S
    Chiu, E
    Lloyd, J
    JOURNAL OF MEDICAL GENETICS, 1996, 33 (12) : 1051 - 1052
  • [50] Diagnostic and presymptomatic testing for Huntington's disease in the prison setting
    Huson, SM
    Hayden, F
    Blair, E
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76